The industry urgently needs to understand that its current approach to policy is almost pre-destined to deliver disappointment and poor outcomes. …
The choice is to be more defensive or continue to suffer bad outcomes
September 19, 2022 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Noxopharm pushes Sofra platform towards cancer proof of concept
August 26, 2026 - - Australian Biotech -
Argent BioPharma takes CannEpil into US veterinary regulatory process
August 26, 2026 - - Latest News -
Entropy takes TRP-8803 to the US in head-to-head depression trial
August 26, 2026 - -
Neuren’s first dividend signals a new phase built on DAYBUE royalties
August 26, 2026 - - Australian Biotech -
Starpharma narrows loss as Genentech deal lifts revenue and new funding extends runway
August 26, 2026 - - Australian Biotech -
Genetic Signatures and Microba explore merger to build infectious disease diagnostics group
August 26, 2026 - - Australian Biotech -
Australian company secures European approval for rare disease treatment
August 26, 2026 - - Latest News